Effect of Lactoferrin Supplementation on Inflammation, Immune Function, and Prevention of Respiratory Tract Infections in Humans: A Systematic Review and Meta-analysis
Open Access
- 27 April 2022
- journal article
- review article
- Published by Elsevier in Advances in Nutrition
- Vol. 13 (5) , 1799-1819
Abstract
Lactoferrin (Lf) is a glycoprotein present in human and bovine milk with antimicrobial and immune-modulating properties. This review aimed to examine the evidence for the effect of Lf supplementation on inflammation, immune function, and respiratory tract infections (RTIs) in humans. Online databases were searched up to December 2020 to identify relevant, English-language articles that examined the effect of Lf supplementation in human subjects of all ages, on either inflammation, immune cell populations or activity, or the incidence, duration, or severity of respiratory illness or RTIs. Twenty-five studies (n = 20 studies in adults) were included, of which 8 of 13 studies (61%) in adults reported a decrease in at least 1 systemic inflammatory biomarker. Immune function improved in 6 of 8 studies (75%) in adults, with changes in immune cell populations in 2 of 6 studies (33%), and changes in immune cell activity in 2 of 5 studies (40%). RTI outcomes were reduced in 6 of 10 studies (60%) (n = 5 in adults, n = 5 in children), with decreased incidence in 3 of 9 studies (33%), and either decreased frequency (2/4, 50%) or duration (3/6, 50%) in 50% of studies. In adults, Lf reduced IL-6 [mean difference (MD): –24.9 pg/mL; 95% CI: –41.64, –8.08 pg/mL], but not C-reactive protein (CRP) [standardized mean difference: –0.09; 95% CI: –0.82, 0.65], or NK cell cytotoxicity [MD: 4.84%; 95% CI: –3.93, 13.60%]. RTI incidence was reduced in infants and children (OR: 0.78; 95% CI: 0.61, 0.98) but not in adults (OR: 1.00; 95% CI: 0.76, 1.32). Clinical studies on Lf supplementation are limited, although findings show 200 mg Lf/d reduces systemic inflammation, while formulas containing 35–833 mg Lf/d may reduce RTI incidence in infants and children, suggesting improved immune function. Future research is required to determine optimal supplementation strategies and populations most likely to benefit from Lf supplementation. This trial was registered at PROSPERO (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021232186) as CRD42021232186.Keywords
This publication has 84 references indexed in Scilit:
- Plasmacytoid dendritic cells and their Toll-like receptor 9 expression selectively decrease with ageHuman Immunology, 2012
- Gut Balance, a synbiotic supplement, increases fecal Lactobacillus paracasei but has little effect on immunity in healthy physically active individualsGut Microbes, 2012
- Bovine Lactoferrin Can Be Taken Up by the Human Intestinal Lactoferrin Receptor and Exert BioactivitiesJournal of Pediatric Gastroenterology and Nutrition, 2011
- Inhibition of SARS Pseudovirus Cell Entry by Lactoferrin Binding to Heparan Sulfate ProteoglycansPLOS ONE, 2011
- Antiviral Properties of Lactoferrin—A Natural Immunity MoleculeMolecules, 2011
- Apo‐ and holo‐lactoferrin are both internalized by lactoferrin receptor via clathrin‐mediated endocytosis but differentially affect ERK‐signaling and cell proliferation in caco‐2 cellsJournal of Cellular Physiology, 2011
- Lactoferrin efficacy versus ferrous sulfate in curing iron deficiency and iron deficiency anemia in pregnant womenBioMetals, 2010
- Effect of Orally Administered Bovine Lactoferrin on the Growth of Adenomatous Colorectal Polyps in a Randomized, Placebo-Controlled Clinical TrialCancer Prevention Research, 2009
- CD56bright natural killer (NK) cells: an important NK cell subsetImmunology, 2009
- Identification of the bactericidal domain of lactoferrinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992